IDH1 and cholangiocarcinoma: Regarding IDH1 mutations in CCA, the main drugs in clinical trial phases are LY3410738 and BAY1436032, both currently in phase I clinical stages, enrolling patients with IDH1 mutation-positive advanced CAA [332, 333].